Polycythemia vera (PV) is relatively uncommon in early adulthood, and evidence about the prevalence of the Janus kinase 2 (JAK2) V617F mutation in the general population is limited. Here, we report a previously healthy volunteer peripheral blood stem cell (PBSC) donor who developed symptomatic PV with the JAK2 V617F mutation 2 years after PBSC mobilization and harvest. The characteristic mutation was identified retrospectively in the blood sample of the donor at the confirmation typing stage, which was before granulocyte colony-stimulating factor injection. This report presents a safety issue for both donor and recipient of hematopoietic stem cell transplantation. Clinicians should be aware of this during health workup and postdonation follow-up of unrelated PBSC donors. Any abnormal and/or equivocal laboratory data, especially during the donor workup stage, should not be overlooked.
Introduction

G
ranulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) have become the major stem cell source for allogeneic hematopoietic stem cell (HSC) transplantation over the past decade. Although most donors experience the discomfort of varying severity during mobilization and/or leukapheresis, PBSC collection in unrelated donors is generally safe [1, 2] . G-CSF injection may cause a dramatic rise in the leukocyte count, along with a modest decrease in the hemoglobin level and platelet count. The blood cell counts return to baseline levels by 1 month after cessation of G-CSF administration [1, 2] . No specific association has been found between transient variations in the blood cell counts and hematologic malignancies after G-CSF mobilization [3] . No case of acute myelogenous leukemia or myelodysplasia was reported in a prospective study of 2408 unrelated PBSC donors in the National Marrow Donor Program [1] . Myeloproliferative neoplasms (MPNs) have not been reported in PBSC donors who underwent G-CSF mobilization and stem cell harvest. We report a young woman who underwent PBSC harvest and was diagnosed with Janus kinase 2 (JAK2) V617F mutation polycythemia vera (PV) 2 years after donation. to insufficient product CD34 + cells in the first harvest, another leukapheresis was performed after the 6 th dose of G-CSF on the following day. Before the first leukapheresis, moderate leukocytosis (29,390/μL) and mild thrombocytosis (511,000/μL) were identified. The hemoglobin and hematocrit levels were 14.5 g/dL and 46.8%, respectively. The donor tolerated the whole procedure of PBSC harvest well. Her leukocyte count peaked after the 6 th dose of G-CSF, and the platelet counts were slightly decreased after leukapheresis. The hemoglobin and hematocrit levels were also decreased but were still relatively high for females [ Figure 1 ]. The preharvest CD34 + cell was 40.96/μL and the final product CD34
+ cell yield after two collections was 4.85 × 10 6 /kg of the recipient's body weight.
Slowly elevating hemoglobin and hematocrit levels without specific discomfort were noted during serial postdonation follow-ups [ Figure 1 ]. The donor was referred to a hematologist for further evaluation 25 months after harvest. She complained of mild headaches, fatigue, and exertional dyspnea for a few months. Extremely high hemoglobin (20.5 g/dL) and hematocrit (62.4%) levels were found, and PV was diagnosed after the characteristic JAK2 V617F mutation was identified by polymerase chain reaction. She then underwent serial phlebotomy and follow-up for PV. Her blood sample at the stage of HLA confirmation typing was retrospectively examined and was positive for the JAK2 V617F mutation. From the limited information reported by the transplantation center, the recipient had not developed any symptoms of PV, but further detailed laboratory results were not available.
Discussion
PV is a clonal hematologic disorder, characterized by unwarranted red blood cell production. Patients have increased risks of thrombosis, myelofibrosis, and secondary acute myeloid leukemia [4] . The JAK2 V617F mutation which results in cytokine-independent growth of hematopoietic cells presents in about 95% patients with PV [5] . To the best of our knowledge, this is the first report of PV diagnosed in an unrelated donor after PBSC donation. The asymptomatic mutation was present before G-CSF administration.
There is limited and controversial evidence about the prevalence of the JAK2 V617F mutation in the general population [6] [7] [8] . In a large Demark cohort of 49,488 participants, the JAK2 V617F mutation was detected in 63 individuals, and 48 (76%) of them were eventually diagnosed with MPNs after a median follow-up of 5.4 years [6] . The annual increments of the JAK2 V617F mutation burden and hematocrit were 0.55% and 1.19%, respectively [6] . The allele burden of the JAK2 V617F mutation correlates with the clinical phenotype and disease complications of MPNs [9] . In our donor, the initial asymptomatic, unidentified JAK2 V617F mutation with borderline hemoglobin and hematocrit levels developed into symptomatic PV within 2 years. Although we did not check the quantitative PCR to compare the mutation burden, the incremental hematocrit after G-CSF mobilized PBSC donation was greater (5% per year).
JAK proteins play an important role in the activation of cytokine receptors, which include the G-CSF receptor, through the Janus kinase/signal transducer and activator of transcription signaling pathway after binding with corresponding cytokine ligands [5] . Passamonti et al. reported constitutive activation of granulocytes and an increased number of circulating CD34 + cells in MPN patients with the JAK2 V617F mutation [10] . The consequences of exogenous short-term G-CSF activation in persons with the JAK2 V617F mutation remain an interesting question. The leukocyte count and circulating CD34 + cell count of our donor were not extraordinarily high after G-CSF mobilization. Her hemoglobin and hematocrit levels were slightly decreased, whereas the elevated platelet count was an unusual finding compared with that in the literature [1, 2] .
This case represents a safety consideration for HSC harvest from donors with subclinical JAK2 V617F mutations. Individuals with the characteristic mutation should be permanently deferred from HSC donation, not only because these donors are at risk of evolution to symptomatic MPNs but also because of the possibility of transmission of the mutated JAK2 gene to recipients. Any equivocal laboratory data during donor workup, mobilization/harvest, and postdonation follow-up should not be overlooked. JAK2 V617F mutation should be carefully clarified in all donors with high hemoglobin and/or hematocrit levels. Further investigation is needed to determine whether PBSC mobilization by G-CSF injection accelerates the natural course of PV.
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